Fermenta Biotech Q1 FY27 Results: Revenue Rs 121 Cr, PAT Rs 9 Cr and Key Highlights
- August 12, 2026
- Posted by: Ankit Jaiswal
- Category: News
Fermenta Biotech Q1 FY27: Revenue Rs 121 Cr (-10.60% YoY). PAT Rs 9 Cr (-55.88% YoY). Results August 11, 2026. CMP Rs 471.50.
Fermenta Biotech Q1 FY27 results were announced on August 11, 2026, reporting a net profit (PAT) of Rs 9 crore, down 55.88% from Rs 21 crore in Q1 FY26. Revenue from operations contracted 10.60% year on year to Rs 121 crore from Rs 136 crore in Q1 FY26. The Fermenta Biotech Q1 FY27 results are on a consolidated basis for the quarter ended June 30, 2026.
Click Here – Get Free Investment Predictions
Fermenta Biotech Q1 FY27 Financial Highlights
The table below summarises the key financial metrics from the Fermenta Biotech Q1 FY27 results compared with the same quarter of the previous year (Q1 FY26).
| Metric | Q1 FY27 (Jun 2026) | Q1 FY26 (Jun 2025) | YoY Change |
|---|---|---|---|
| Revenue from Operations (Rs Cr) | Rs 121 Cr | Rs 136 Cr | -10.60% |
| Gross Profit (Rs Cr) | Rs 12 Cr | Rs 22 Cr | -42.66% |
| Net Profit / (Loss) – PAT (Rs Cr) | Rs 9 Cr | Rs 21 Cr | -55.88% |
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction stock opportunities, investors pay attention.
Our research team has shortlisted the Top Stocks to Buy based on current market momentum, sector trends and growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks on Univest
Fermenta Biotech Q1 FY27 Performance Analysis
Use the Univest Screener to Track Live Fundamentals of Indian Stocks
Fermenta biotech q1 fy27 results show a revenue decline of 10.6% year on year to Rs 121 crore. Gross profit declined to Rs 12 crore from Rs 22 crore in Q1 FY26.
Net profit in the June 2026 quarter stood at Rs 9 crore, a 55.88% decrease year on year. Investors tracking Fermenta Biotech quarterly results should verify these figures against the official BSE and NSE filings.
Key Business Factors in Fermenta Biotech Q1 FY27
1. Revenue Trend Sets the Quarterly Context
Revenue contracted 10.60% year on year to Rs 121 crore, reflecting near-term headwinds in the Pharmaceuticals and Biotechnology segment.
2. Gross Profit and Margin Movement
Gross profit fell to Rs 12 crore from Rs 22 crore in Q1 FY26. Higher input costs or pricing pressure weighed on gross margins.
3. Net Profit Outcome in the June Quarter
PAT came in at Rs 9 crore, down 55.88% from Rs 21 crore in Q1 FY26. Consistent profitability will depend on revenue momentum and margin trends through FY27.
Dividend Details
No dividend has been declared alongside the Fermenta Biotech quarterly results for the quarter ended June 2026. Investors may track future announcements via BSE India and NSE India portals.
Fermenta Biotech FY27 Outlook After Q1 Results
The June 2026 quarterly performance of Fermenta Biotech presents a mixed picture heading into the rest of FY27. Gross margin improvement will be critical for the company to strengthen its financial position. Investors tracking Fermenta Biotech Q1 results should monitor management guidance, sector demand in Pharmaceuticals and Biotechnology, and any strategic moves that could alter the earnings trajectory.
Fermenta Biotech Stock Performance
Download the Univest iOS App or Univest Android App to track Fermenta Biotech live share price and upcoming quarterly results.
Fermenta Biotech share price stood at Rs 471.50 on August 11, 2026, the day the quarterly results were declared. Post-results, the market will assess whether the Pharmaceuticals and Biotechnology company’s financial performance justifies the current valuation. Investors should verify the latest price and fundamentals on BSE and NSE before making any investment decision.
Key Risks to Watch After Fermenta Biotech Q1 FY27 Results
1. Sector-Specific Demand Headwinds
A slowdown in the Pharmaceuticals and Biotechnology sector could weigh on Fermenta Biotech revenue and profitability beyond what the June 2026 quarter already reflects.
2. Input Cost and Margin Pressure
Rising raw material or operational costs could compress gross margins and limit net profit recovery in subsequent quarters of FY27.
3. Macroeconomic and Regulatory Uncertainty
Inflation, interest rate movements, and regulatory changes remain key risks to the earnings trajectory of Fermenta Biotech through FY27.
Conclusion
Fermenta Biotech Q1 FY27 results report revenue of Rs 121 crore and a net profit (PAT) of Rs 9 crore, down 55.88% from Rs 21 crore in Q1 FY26. The June 2026 quarterly performance reflects the company’s position in the Pharmaceuticals and Biotechnology space. Investors should study the full financials on BSE and NSE and consult a SEBI-registered advisor before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Fermenta Biotech Q1 FY27 Results
When were the Fermenta Biotech Q1 FY27 results announced?
Ans. The June 2026 quarterly results for Fermenta Biotech were announced on August 11, 2026, covering the quarter ended June 30, 2026. The consolidated results were filed with BSE and NSE on the same date.
What is the PAT in the Fermenta Biotech Q1 FY27 results?
Ans. PAT (net profit) stood at Rs 9 crore in the June 2026 quarter, down 55.88% from Rs 21 crore in Q1 FY26.
What was the revenue in the Fermenta Biotech Q1 FY27 results?
Ans. Revenue for the June 2026 quarter fell 10.60% year on year to Rs 121 crore from Rs 136 crore in Q1 FY26.
Did Fermenta Biotech announce any dividend with the Q1 FY27 results?
Ans. No dividend has been declared alongside the June 2026 quarterly results. Investors may track future Fermenta Biotech dividend announcements through the BSE and NSE portals.
What is the Fermenta Biotech FY27 outlook after Q1 results?
Ans. The June 2026 quarterly performance signals a challenging start to FY27 for Fermenta Biotech. Key factors to watch include revenue trends, margin performance, and Pharmaceuticals and Biotechnology sector demand through the rest of the financial year.
Is Fermenta Biotech a good buy after Q1 FY27 results?
Ans. The Q1 FY27 financial performance of Fermenta Biotech reflects challenging trends in the June 2026 quarter. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor.
